Archaeal lipid mucosal vaccine adjuvant and delivery system

2010 ◽  
Vol 9 (4) ◽  
pp. 431-440 ◽  
Author(s):  
Girishchandra B Patel ◽  
Wangxue Chen
Keyword(s):  
Delivery System ◽  
Mucosal Vaccine ◽  
Vaccine Adjuvant

scholarly journals The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT

mSphere ◽  
2018 ◽  
Vol 3 (4) ◽  
Author(s):  
John D. Clements ◽  
Elizabeth B. Norton
Keyword(s):  
Cytotoxic T Lymphocytes ◽  
The United States ◽  
Mechanisms Of Action ◽  
Mucosal Vaccine ◽  
Vaccine Adjuvant ◽  
Specific Response ◽  
Preclinical Studies ◽  
Content Type ◽  
Clinical Investigations ◽  
Iga Antibodies

ABSTRACTPerhaps the best-studied mucosal adjuvants are the bacterially derived ADP-ribosylating enterotoxins. This adjuvant family includes heat-labile enterotoxin ofEscherichia coli(LT), cholera toxin (CT), and mutants or subunits of LT and CT. These proteins promote a multifaceted antigen-specific response, including inflammatory Th1, Th2, Th17, cytotoxic T lymphocytes (CTLs), and antibodies. However, more uniquely among adjuvant classes, they induce antigen-specific IgA antibodies and long-lasting memory to coadministered antigens when delivered mucosally or even parenterally. The purpose of this minireview is to describe the general properties, history and creation, preclinical studies, clinical studies, mechanisms of action, and considerations for use of the most promising enterotoxin-based adjuvant to date, LT(R192G/L211A) or dmLT. This review is timely due to completed, ongoing, and planned clinical investigations of dmLT in multiple vaccine formulations by government, nonprofit, and industry groups in the United States and abroad.

scholarly journals Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity

2018 ◽  
Vol 46 (sup1) ◽  
pp. 852-860 ◽  
Author(s):  
Wenjing Qu ◽  
Na Li ◽  
Rui Yu ◽  
Wenbao Zuo ◽  
Tingting Fu ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Mucosal Vaccine ◽  
Vaccine Adjuvant

scholarly journals Cholesteryl Pullulan Encapsulated TNF-αNanoparticles Are an Effective Mucosal Vaccine Adjuvant against Influenza Virus

2015 ◽  
Vol 2015 ◽  
pp. 1-15 ◽  
Author(s):  
Daiki Nagatomo ◽  
Madoka Taniai ◽  
Harumi Ariyasu ◽  
Mutsuko Taniguchi ◽  
Miho Aga ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Influenza Virus Infection ◽  
Repeated Administration ◽  
Mucosal Vaccine ◽  
Nasal Administration ◽  
Vaccine Adjuvant ◽  
Severe Toxicity ◽  
Lethal Challenge ◽  
Antigen Uptake ◽  
Humoral And Cellular Immunity

We encapsulated tumor necrosis factor-α(TNF-α), a major proinflammatory cytokine, into cholesteryl pullulan (CHP) to prepare TNF/CHP nanoparticles. In this report, we describe the immune-enhancing capability of the nanoparticles to act as a vaccine adjuvant. TNF/CHP nanoparticles showed excellent storage stability and enhanced host immune responses to external immunogens. The nanoparticles were effective via the nasal route of administration for inducing systemic IgG1as well as mucosal IgA. We applied the nanoparticles in a model experimental influenza virus infection to investigate their adjuvant ability. TNF/CHP nanoparticles combined with a conventional split vaccine protected mice via nasal administration against a lethal challenge of A/PR/8/34 (H1N1) influenza virus. Mechanistic studies showed that the nanoparticles enhanced antigen uptake by dendritic cells (DCs) and moderately induced the expression of inflammation-related genes in nasopharynx lymphoid tissue (NALT), leading to the activation of both B and T cells. Preliminary safety study revealed no severe toxicity to TNF/CHP nanoparticles. Slight-to-moderate influences in nasal mucosa were observed only in the repeated administration and they seemed to be reversible. Our data show that TNF/CHP nanoparticles effectively enhance both humoral and cellular immunity and could be a potential adjuvant for vaccines against infectious diseases, especially in the mucosa.

Production of biologically active CXC chemokines by Lactococcus lactis: Evaluation of its potential as a novel mucosal vaccine adjuvant

Vaccine ◽  
2008 ◽  
Vol 26 (46) ◽  
pp. 5778-5783 ◽  
Author(s):  
Naima G. Cortes-Perez ◽  
Luis F. da Costa Medina ◽  
François Lefèvre ◽  
Philippe Langella ◽  
Luis G. Bermúdez-Humarán
Keyword(s):  
Lactococcus Lactis ◽  
Biologically Active ◽  
Mucosal Vaccine ◽  
Vaccine Adjuvant
Sign in / Sign up

Export Citation Format

Share Document